Psychological Effects During Reduced Training in Distance Runners*

AF Wittig,Houmard Ja,D. Costill

DOI: https://doi.org/10.1055/s-2007-1024882

1989-04-01

International Journal of Sports Medicine

Abstract:P P P P

What problem does this paper attempt to address?

P925: PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA

Wenming Chen,Zhongxia Huang,Baijun Fang,Yuqin Song,Hongmei Jing,Zhongjun Xia,Zhen Cai,Gang An,Huixing Zhou,Nian Liu,Xin LI,Yuzhang Liu,Lingyan Ping,Wei Wan,Xiaoqin Chen,Jingsong He,Yan Xu

DOI: https://doi.org/10.1097/01.hs9.0000970604.12677.40

2023-01-01

HemaSphere

Abstract:Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory lymphoma are malignancies that pose significant therapeutic challenges. CM313, an anti-CD38 monoclonal antibody, has demonstrated preclinical anti-tumor activity in both MM and lymphoma through antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis. Aims: To characterize the safety and preliminary efficacy of CM313 in adult patients (pts) with RRMM or relapsed/refractory lymphoma (mainly limited to Waldenstrom’s macroglobulinemia and marginal zone lymphoma [MZL]). Methods: This open-label, multicenter, phase 1 trial (NCT04818372) consisted of a modified dose-escalation phase (Part A) and a dose-expansion phase (Part B). Eligible patients (aged 18-75 years) had a relapse or become refractory to prior therapies and were required to have measurable disease. In Part A, pts were treated with CM313 at doses of 0.006, 0.06, 0.3, 1.0, 2.0, 4.0, 8.0, 16.0, and 24.0 mg/kg. Dose-limiting toxicities (DLTs) were assessed over a 21-day cycle following the first infusion. The recommended doses of CM313 for Part B were 4.0, 8.0, and 16.0 mg/kg. CM313 was administered intravenously once weekly for the first 8 cycles, then every 2 weeks for 8 cycles (cycles 9-16), and then every 4 weeks onwards until disease progression or unacceptable toxicity. The primary endpoints were safety and tolerability for Part A and overall response rate (ORR) for Part B. Results: As of October 10, 2022, 34 pts were enrolled in the trial, with 17 in Part A (all RRMM) and 17 in Part B (14 RRMM and 3 MZL). Median age was 59 years (range 39-74). Pts had received a median of 3 prior lines of therapies (range 1-10). The maximum tolerated dose was not reached, and no DLTs were observed. Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported in 15/34 (44.1%) pts (8 [23.5%] were considered drug related); there were no grade 5 TEAEs. 5 (14.7%) pts experienced at least one serious adverse event (2 [5.9%] were considered drug related). The most frequent drug-related TEAEs (≥20% of pts) were infusion-related reaction (IRR; 50.0%), lymphocyte count decreased (35.3%), white blood cell count decreased (32.4%), and neutrophil count decreased (20.6%). All IRRs were grade 1/2 and occurred during the first and/or second infusions. Among the 29 out of 31 RRMM pts (93.5%) who had at least one post-baseline efficacy assessment, ORR was 34.5% (95%CI: 17.94-54.33; 10 of 29), with an ORR of 33.3% in 16.0 mg/kg cohort (Figure). At a median follow-up of 6 months (range 0.4-17.5), the median progression free survival for the 29 RRMM pts was 132 days (95%CI: 49.0-193.0), and the median overall survival was not reached yet.Summary/Conclusion: CM313 monotherapy demonstrated preliminary promising clinical efficacy with tolerable and manageable safety profile. Further studies are ongoing and planned. Keywords: Multiple myeloma, Lymphoma, Relapsed lymphoma, Refractory
Radioligand Therapy in Lymphoma: Past, Present, and Future

Ludmila Santiago Almeida,Roberto C Delgado Bolton,Victor Cabral Heringer,Samuel de Souza Medina,Elba Etchebehere

DOI: https://doi.org/10.1016/j.cpet.2024.05.003

Abstract:In the1980s, radiolabeled cells helped understand the pathology of hemato-oncology. In the 1990s, preclinical trials evaluated radiolabeled immunotherapy with monoclonal antibodies (MoAbs) such as anti-CD20 agents labeled with Iodine-131 (Bexxar) or Yttrium-90 (Zevalin). Due to the safe and durable responses of radiolabeled MoAbs, the Food and Drug Administration approved these agents in the 2000s. Despite radioimmunotherapy's long journey, its application has recently decreased. This review will discuss the historical timeline of radioimmunotherapy, debate on advantages and difficulties, and explore trials. We will examine future directions of radioligand therapy in hemato-oncology, considering emerging molecules that may become the next theragnostic trend.
Safety and dosimetry evaluation of radioimmunotherapy using 177Lu-labeled antibodies in lymphoma

Lei Kang,Dawei Jiang,Emily Ehlerding,Todd Barnhart,Carolina Ferreira,Rongfu Wang,Jonathan Engle,Weibo Cai

2019-01-01

Abstract:1004 Purpose: Radioimmunotherapy (RIT) can selectively kill tumor cells while sparing normal tissues based on the targeted ability of antibodies. CD38 has been considered a promising biomarker for some CD38-positive lymphomas. The aim of the study was to estimate the biosafety and radiation-absorbed doses of the application of lutetium-177 (177Lu) labeled a CD38-specific antibody in a preclinical lymphoma model. Methods: Daratumumab, a CD38-specific FDA-approved monoclonal antibody, was labeled with 177Lu (t1/2 = 6.65 d) after conjugatied with diethylenetriaminepentaacetic acid (DTPA). A CD38-positive lymphoma murine model was built after injection of Ramos cells subcutaneously in CB/17 nude mice. 177Lu-DTPA-daratumumab was administrated via tail vein at the same dose of about 7.4 MBq, along with two control groups including PBS and 177Lu-only. After the administration in lymphoma model, each group was monitored every other day including tumor sizes and body weight. Balb/c normal mice were also evaluated after the same dose of 177Lu-DTPA-daratumumab. Hematological analysis and biodistribution were performed every three days during the period of treatment. Dosimetry was calculated based on the biodistribution data. Finally, major organs were evaluated by histological staining at the end time point. Results: The radiolabeling yield of 177Lu-DTPA-daratumumab was more than 90%. Tumor growth was significantly slowed and decreased after treated with 177Lu-DTPA-daratumumab, compared with PBS and 177Lu only. Even the body weight dropped after the administration of 177Lu-DTPA-daratumumab in lymphoma bearing CB/17 nude mice, the body weight of balb/c normal mice didn’t drop after the same administration. This suggested that the dropped body weight was probably related with this species of nude mice. Hematological study showed that only WBC dropped a little at the early stage of treatment but recovered soon. Other blood cells all located in normal range during the period of treatment. Hematoxylin - eosin staining results showed that major organs maintained their normal structure and shape except for large necrosis inside of tumor after treated with 177Lu-DTPA-daratumumab. After injection of 177Lu only, liver tissue was found deformation and necrosis, suggesting liver toxicity of 177Lu. The effective dose of total body was 0.15±0.02 mSv/MBq for 177Lu-DTPA-daratumumab. Conclusions: 177Lu-DTPA-daratumumab therapy is an effective method for CD38-positive lymphoma, along with little side effect and high safety in murine model. It deserves further exploration in the future clinic.
Integrated DC-DC converter with an auxiliary output stage for transient suppression

J. Wang,K. Ng,T. Kawashima,M. Sasaki,H. Nishio,A. Prodić,W. Ng

DOI: https://doi.org/10.1109/EDSSC.2009.5394236

2009-12-01

Abstract:In this paper, the transistor sizing of an auxiliary output stage in a digitally controlled transient suppression system for fully integrated point-of-load (POL) DC-DC converters is investigated. The auxiliary output stage is added in parallel to the main output switching stage to help reduce output voltage deviation during load transient. The sizing of the auxiliary output stage in relation to the main output stage is studied through analysis and simulation of a 3 W, 12 V to 1 V buck converter. The auxiliary output stage performs well with transistors occupying as little as 5% the area of the main output stage.
Cure of Disseminated Human Lymphoma with [177Lu]Lu-Ofatumumab in a Preclinical Model

Kyuhwan Shim,Mark S. Longtine,Richard L. Wahl,Diane S Abou,Mark J Hoegger,Richard S Laforest,Daniel LJ Thorek

DOI: https://doi.org/10.2967/jnumed.122.264816

2023-04-04

Journal of Nuclear Medicine

Abstract:Although immunotherapies that target CD20 on most non-Hodgkin lymphoma (NHL) cells have improved patient outcomes, current therapies are inadequate because many cases are, or become, refractory or undergo relapse. Here, we labelled the third-generation human anti-CD20 antibody ofatumumab with 177 Lu, determined the in vitro characteristics of [ 177 Lu]Lu-ofatumumab, estimated human dosimetry, and assayed tumor targeting and therapeutic efficacy in a murine model of disseminated NHL. Methods: CHX-A''-diethylenetriaminepentaacetic acid-[ 177 Lu]Lu-ofatumumab was prepared. We evaluated radiochemical yield, purity, in vitro immunoreactivity, stability, ( n = 7), affinity, and killing of CD20-expressing Raji cells ( n = 3). Human dosimetry was estimated from biodistribution studies as percentage injected activity per gram using C57BL/6N mice. Tissue and organ biodistribution was determined in R2G2 immunodeficient mice with subcutaneous Raji-cell tumors. Therapy studies used R2G2 mice with disseminated human Raji-luc tumor cells ( n = 10 mice/group). Four days after cell injection, the mice were left untreated or were treated with ofatumumab, 8.51 MBq of [ 177 Lu]Lu-IgG, or 0.74 or 8.51 MBq of [ 177 Lu]Lu-ofatumumab. Survival, weight, and bioluminescence were tracked. Results: Radiochemical yield was 93% ± 2%, radiochemical purity was 99% ± 1%, and specific activity was 401 ± 17 MBq/mg. Immunoreactivity was substantially preserved, and more than 75% of 177 Lu remained chelated after 7 d in serum. [ 177 Lu]Lu-ofatumumab specifically killed Raji-luc cells in vitro ( P < 0.05). Dosimetry estimated that an effective dose for human administration is 0.36 mSv/MBq and that marrow may be the dose-limiting organ. Biodistribution in subcutaneous tumors 1, 3, and 7 d after [ 177 Lu]Lu-ofatumumab injection was 11, 15, and 14 percentage injected activity per gram, respectively. In the therapy study, median survival of untreated mice was 19 d, not statistically different from mice treated with 8.51 MBq of [ 177 Lu]Lu-IgG (25 d). Unlabeled ofatumumab increased survival to 46 d, similar to 0.74 MBq of [ 177 Lu]Lu-ofatumumab (59 d), with both being superior to no treatment ( P < 0.0003). Weight loss and increased tumor burden preceded death or killing of the animal for cause. In contrast, treatment with 8.51 MBq of [ 177 Lu]Lu-ofatumumab dramatically increased median survival (>221 d), permitted weight gain, eliminated detectable tumors, and was curative in 9 of 10 mice. Conclusion: [ 177 Lu]Lu-ofatumumab shows favorable in vitro characteristics, localizes to tumor, and demonstrates curative therapeutic efficacy in a disseminated lymphoma model, showing potential for clinical translation to treat NHL.

radiology, nuclear medicine & medical imaging
Targeted Alpha Therapy with [225Ac]Ac-Macropa-Isatuximab for CD38-positive Hematological Malignancies

Natalia Herrero Alvarez,David Bauer,Alexa L. Michel,Lukas M. Carter,Jason S. Lewis

DOI: https://doi.org/10.1101/2024.11.01.621584

2024-11-03

Abstract:Background: Hematological malignancies include diverse cancers related to immune system cells and blood-forming tissue. Treatment resistance and relapse are common despite the introduction of novel therapeutics. Following the development of the PET probe [89Zr]Zr-DFO-isatuximab, targeting the overexpressed CD38 receptor, we developed [225Ac]Ac-Macropa-isatuximab for targeted alpha therapy in murine models of human multiple myeloma (MM) and lymphoma. Methods: In vitro studies were performed using the CD38 expressing MM1.S (human MM) and Daudi (human lymphoma). Radiopharmaceutical therapy studies were performed in female NSG mice, and the disseminated disease models were established by intravenous injection of luciferase-transfected cells. Mice were randomized (n = 10 mice per cohort) and received a high activity (5.5 kBq) or low activity (2.7 kBq) of [225Ac]Ac-Macropa-Isatuximab in single or multiple cycles. Controls receiving untargeted [225Ac]Ac-Macropa-IgG or saline were included. Tumor burden was measured by bioluminescence imaging (BLI). Weight loss greater than 20% or leg paralysis were used as endpoints. Results: [225Ac]Ac-Macropa-Isatuximab was obtained with high radiochemical yield and purity (>95%). It displayed high immunoreactivity and excellent stability in human serum over 10 days. The therapeutic effect of [225Ac]Ac-mcp-Isatuximab was significant for all the treatment cohorts compared to the saline control after administration of the first cycle. Low activities were better tolerated in general, resulting in extended median survivals. The most successful regimen in the MM model was the dual cycle of low activity, with a median survival of 60 days (P < 0.001). In the lymphoma model, the single high activity of 5.5 kBq and four low activity of 2.7 kBq resulted in similar median survivals of 143 days (P < 0.0001) and 147 days (P < 0.0001). These regimens resulted in complete responses with no detectable cancer cells in some cases. Remarkably, no significant kidney damage was observed in any of the models. Conclusion: [225Ac]Ac-Macropa-Isatuximab selectively targets CD38, reducing tumor growth and, in some cases, tumor eradication, especially when applied in multiple cycles. Importantly, it has not been associated with significant toxicities at levels of administered activity required for therapeutic benefit, indicating its promise as a therapeutic option.

Pharmacology and Toxicology
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma

Anju Wadhwa,Sinan Wang,Bonell Patiño-Escobar,Anil P Bidkar,Kondapa Naidu Bobba,Emily Chan,Niranjan Meher,Scott Bidlingmaier,Yang Su,Suchi Dhrona,Huimin Geng,Vishesh Sarin,Henry F VanBrocklin,David M Wilson,Jiang He,Li Zhang,Veronica Steri,Sandy W Wong,Thomas G Martin,Youngho Seo,Bin Liu,Arun P Wiita,Robert R Flavell

DOI: https://doi.org/10.1158/1078-0432.CCR-23-2130

2024-03-01

Abstract:Purpose: Multiple myeloma is a plasma cell malignancy with an unmet clinical need for improved imaging methods and therapeutics. Recently, we identified CD46 as an overexpressed therapeutic target in multiple myeloma and developed the antibody YS5, which targets a cancer-specific epitope on this protein. We further developed the CD46-targeting PET probe [89Zr]Zr-DFO-YS5 for imaging and [225Ac]Ac-DOTA-YS5 for radiopharmaceutical therapy of prostate cancer. These prior studies suggested the feasibility of the CD46 antigen as a theranostic target in multiple myeloma. Herein, we validate [89Zr]Zr-DFO-YS5 for immunoPET imaging and [225Ac]Ac-DOTA-YS5 for radiopharmaceutical therapy of multiple myeloma in murine models. Experimental design: In vitro saturation binding was performed using the CD46 expressing MM.1S multiple myeloma cell line. ImmunoPET imaging using [89Zr]Zr-DFO-YS5 was performed in immunodeficient (NSG) mice bearing subcutaneous and systemic multiple myeloma xenografts. For radioligand therapy, [225Ac]Ac-DOTA-YS5 was prepared, and both dose escalation and fractionated dose treatment studies were performed in mice bearing MM1.S-Luc systemic xenografts. Tumor burden was analyzed using BLI, and body weight and overall survival were recorded to assess antitumor effect and toxicity. Results: [89Zr]Zr-DFO-YS5 demonstrated high affinity for CD46 expressing MM.1S multiple myeloma cells (Kd = 16.3 nmol/L). In vitro assays in multiple myeloma cell lines demonstrated high binding, and bioinformatics analysis of human multiple myeloma samples revealed high CD46 expression. [89Zr]Zr-DFO-YS5 PET/CT specifically detected multiple myeloma lesions in a variety of models, with low uptake in controls, including CD46 knockout (KO) mice or multiple myeloma mice using a nontargeted antibody. In the MM.1S systemic model, localization of uptake on PET imaging correlated well with the luciferase expression from tumor cells. A treatment study using [225Ac]Ac-DOTA-YS5 in the MM.1S systemic model demonstrated a clear tumor volume and survival benefit in the treated groups. Conclusions: Our study showed that the CD46-targeted probe [89Zr]Zr-DFO-YS5 can successfully image CD46-expressing multiple myeloma xenografts in murine models, and [225Ac]Ac-DOTA-YS5 can effectively inhibit the growth of multiple myeloma. These results demonstrate that CD46 is a promising theranostic target for multiple myeloma, with the potential for clinical translation.
CD46-targeted theranostics for Positron Emission Tomography and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma

Anju Wadhwa,Sinan Wang,Bonell Patiño-Escobar,Anil P. Bidkar,Kondapa Naidu. Bobba,Emily Chan,Niranjan Meher,Scott Bidlingmaier,Yang Su,Suchi Dhrona,Huimin Geng,Vishesh Sarin,Henry F. VanBrocklin,David M. Wilson,Jiang He,Li Zhang,Veronica Steri,Sandy W. Wong,Thomas G. Martin,Youngho Seo,Bin Liu,Arun P. Wiita,Robert R. Flavell

DOI: https://doi.org/10.1158/1078-0432.ccr-23-2130

IF: 13.801

2023-12-19

Clinical Cancer Research

Abstract:Purpose: Multiple myeloma (MM) is a plasma cell malignancy with an unmet clinical need for improved imaging methods and therapeutics. Recently, we identified CD46 as an overexpressed therapeutic target in MM and developed the antibody YS5, which targets a cancer-specific epitope on this protein. Herein, we validate [89Zr]Zr-DFO-YS5 for immunoPET imaging and [225Ac]Ac-DOTA-YS5 for radiopharmaceutical therapy of MM in murine models. Experimental Design: In vitro saturation binding was performed using the CD46 expressing MM.1S MM cell line. ImmunoPET imaging using [89Zr]Zr-DFO-YS5 was performed in immunodeficient (NSG) mice bearing subcutaneous and disseminated MM xenografts. For radioligand therapy, [225Ac]Ac-DOTA-YS5 was prepared, and fractionated dose treatment studies were performed in mice bearing MM1.S-Luc disseminated xenografts. Tumor burden was analyzed using BLI, and body weight and overall survival were recorded. Results: [89Zr]Zr-DFO-YS5 demonstrated high affinity for CD46 expressing MM.1S MM cells (Kd = 16.3 nM). Bioinformatics analysis of human MM samples revealed high CD46 expression. [89Zr]Zr-DFO-YS5 PET/CT specifically detected MM lesions, with low uptake in controls. In the MM.1S disseminated model, localization of uptake on PET imaging correlated well with the luciferase expression from tumor cells. A treatment study using [225Ac]Ac-DOTA-YS5 in the MM.1S disseminated model demonstrated a clear tumor volume and survival benefit in the treated groups. Conclusions: Our study showed that the CD46-targeted probe [89Zr]Zr-DFO-YS5 can successfully image CD46-expressing MM xenografts in murine models, and [225Ac]Ac-DOTA-YS5 can effectively inhibit the growth of MM. These results demonstrate that CD46 is a promising theranostic target for MM, with the potential for clinical translation.

oncology
A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma

Michael Durando,Ajay K Gopal,Joseph Tuscano,Daniel Persky

DOI: https://doi.org/10.1093/oncolo/oyad333

2024-01-11

The Oncologist

Abstract:Abstract Purpose The clinical efficacy of anti-CD20 radioimmunotherapy (RIT) is due to a combination of extracellular mechanisms involving immune-mediated cytotoxicity, and intracellular mechanisms related to inhibition of CD20 signaling and DNA damage from ionizing radiation. In 2002, the first RIT was approved by the U.S. Food and Drug Administration for the treatment of patients with indolent B-cell follicular non-Hodgkin lymphoma (NHL). The 2 approved agents, 90 Y-ibritumomab tiuxetan (90Y-IT, Zevalin, Acrotech Biopharma) and 131 I-tositumomab (131-IT, Bexxar, GlaxoSmithKline) both target CD20. The aim of this study was to review the clinical applications and supporting clinical trial data of anti-CD20 RIT for lymphoma. Methods A review of published articles and abstracts on the clinical efficacy and safety of 90Y-IT and iodine I 131 tositumomab was performed. Results The clinical efficacy and safety of anti-CD20 RIT have been demonstrated in numerous clinical trials and case series. Agents have produced significant responses in patients with follicular NHLs and in off-label applications. Importantly, RIT has demonstrated promising findings in high-risk lymphomas and heavily pretreated and refractory patient populations. Associated toxicity profiles are noted as tolerable, acceptable, and most often reversible. Conclusions In the 2 decades since its approval, anti-CD20 RIT continues to demonstrate efficacy, particularly with a proportion of patients maintaining long-term remissions. The combination of prolonged efficacy, tolerability, and treatment convenience makes RIT a reasonable alternative to other systemic therapies. It is recommended that further research on RIT should focus on biomarkers of long-term response, pretargeting, and sequencing of RIT in the treatment course.

oncology
Effect of 67Cu-2It-bat-lym-1 Therapy on BCL-2 Gene and Protein Expression in a Lymphoma Mouse Model.

LA Kroger,SJ DeNardo,GL DeNardo,CY Xiong,MD Winthrop,PH Gumerlock

IF: 13.801

1999-01-01

Clinical Cancer Research

Abstract:Radioimmunotherapy using monoclonal antibodies against tumor-associated antigens has been particularly promising in the treatment of radiosensitive malignancies such as lymphoma. 67Cu has excellent physical and biochemical properties for radioimmunotherapy. 67Cu-2IT-BAT-Lym-1 has been used in preclinical and clinical trials, where an exceptionally long residence time of 67Cu on tumor was observed. BCL-2, a proto-oncogene that promotes cell survival by blocking apoptotic cell death, is overexpressed in most B-cell lymphomas including Raji human Burkitt's lymphoma cells. In this study, therapeutic efficacy and BCL-2 gene and protein expression levels were examined in Raji xenografts in mice after 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. 67Cu-2IT-BAT-Lym-1 therapy induced a response rate (complete and partial responses) of approximately 50%. BCL-2 gene expression was decreased 3 h after radioimmunotherapy, followed by a decrease in Bcl-2 protein by 24 h. Decreases in BCL-2 gene and protein expression preceding observations of 67Cu-2IT-BAT-Lym-1 therapeutic effect suggest that down-regulation of BCL-2 leaves cells more likely to be killed by low dose-rate radiation from radioimmunotherapy.
Theranostics of Lymphoma with 89Zr- and 177Lu-Labeled Daratumumab

Kang Liu,Dawei Jiang,Emily B. Ehlerding,Carolina A. Ferreira,Bo Yu,Todd Barnhart,Rongfu Wang,Weibo Cai

2018-01-01

Abstract:74 Objectives: Lymphoma is a group of highly heterogeneous malignancies that developed from lymphocytes. Accurate diagnosis and personalized treatment are urgently needed in the era of precision medicine. CD38 is highly expressed on plasma cells, especially on multiple myeloma (MM), suggesting CD38 as a suitable biomarker of MM. Daratumumab is the first anti-CD38 human monoclonal antibody. Based on its good response rate in the treatment of relapsed/refractory MM, daratumumab provides a promising candidate for CD38-targeted applications. In this study, the theranostic role of 89Zr- and 177Lu-labeled daratumumab was investigated for PET imaging and treatment of CD38-positive lymphoma. Methods: Daratumumab was conjugated with desferrioxamine (Df) for radiolabeling with 89Zr (t1/2 = 78.4 h) and it was conjugated with diethylenetriaminepentaacetic acid (DTPA) for radiolabeling with 177Lu (t1/2 = 6.65 d). Western blot (WB) was used to screen CD38 expression in lymphoma cell lines. Competitive cellular binding assay was used to measure binding affinity and cell receptor density. After lymphoma tumor-bearing mice model was established, PET imaging and biodistribution studies were performed after injection of 89Zr-Df-daratumumab. Further, four study groups were employed for the treatment study: PBS, 177Lu-only, 177Lu-DTPA-daratumumab, and 177Lu-DTPA-IgG (human non-specific). Autoradiography, tumor sizes, body weight, and biodistribution were measured within 10 days post-injection. Finally, histological analysis was performed to examine CD38 expression in tumors. Results: For daratumumab radiolabeling with 89Zr and 177Lu, labeling yields were more than 92% (n=9). Daudi cell line was found with significant overexpression of CD38 by WB. Based on competitive cell binding assay, 89Zr-Df-daratumumab showed a Kd value of 1.058 ± 0.16 nM for the Daudi cell line with a receptor density of 1.431 ×105 per cell. PET imaging of 89Zr-Df-daratumumab showed an increased tumor uptake which reached 16.2 ± 2.4 %ID/g at 120 h post-injection for Daudi tumors (n = 4). Immunofluorescent staining verified a strong CD38 expression for Daudi tumor. For the treatment group of 177Lu-DTPA-daratumumab, significant inhibition of tumor growth was observed. In comparison, PBS and 177Lu only groups exhibited continued tumor growth. 18F-FDG imaging results showed the lowest glucose metabolism of tumor in the 177Lu-DTPA-daratumumab group. In all study groups, mouse body weight did not decrease by more than 20%, indicating the safety of the radiolabeled antibody. Autoradiography showed high tumor uptake for the treatment group (i.e. 177Lu-DTPA-daratumumab) while high significant liver uptake after injection of 177Lu only. Biodistribution studies proved high uptake of 177Lu-DTPA-daratumumab at day 10 post-injection (15.2 ± 2.6 %ID/g, n = 3) but low uptake in other organs. Conclusion:89Zr- and 177Lu-labeled daratumumab displayed a significant CD38 positive tumor affinity and effective tumor therapy without significant toxicity. Therefore, 89Zr- and 177Lu-labeled daratumumab should be further investigated in the theranostic field of lymphoma and/or MM in the clinic.
Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation

Kim Orchard,Jonathan Langford,Matthew Guy,Gemma Lewis,Sofia Michopoulou,Margaret Cooper,Clint Zvavamwe,Deborah Richardson,Valerie Lewington

DOI: https://doi.org/10.1038/s41409-024-02317-z

2024-06-14

Bone Marrow Transplantation

Abstract:We report the results of a Phase I radiation dose escalation study using an yttrium-90 ( 90 Y) labelled anti-CD66 monoclonal antibody given with standard conditioning regimen for patients receiving haematopoietic stem cell transplants for myeloid leukaemia or myeloma. The 90 Y-labelled anti-CD66 was infused prior to standard conditioning. In total, 30 patients entered the trial and 29 received 90 Y-labelled mAb, at infused radiation activity levels of 5, 10, 25, or 37.5 megaBequerel (MBq)/kg lean body weight. A prerequisite for receiving the 90 Y-labelled mAb was favourable dosimetry determined by single-photon emission computerised tomography (SPECT) dosimetry following administration of indium-111 ( 111 In) anti-CD66. Estimated absorbed radiation doses delivered to the red marrow demonstrated a linear relationship with the infused activity of 90 Y-labelled mAb. At the highest activity level of 37.5 MBq/kg, mean estimated radiation doses for red marrow, liver, spleen, kidneys and lungs were 24.6 ± 5.6 Gy, 5.8 ± 2.7 Gy, 19.1 ± 8.0 Gy, 2.1 ± 1.1 and 2.2 ± 0.9, respectively. All patients engrafted, treatment-related mortality 1-year post-transplant was zero. Toxicities were no greater than those anticipated for similar conditioning regimens without targeted radiation. The ability to substantially intensify conditioning prior to haematopoietic stem cell transplantation without increasing toxicity warrants further testing to determine efficacy. clinicaltrials.gov identifier: NCT01521611.

oncology,immunology,hematology,transplantation
Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias

J G Jurcic,P C Caron,T K Nikula,E B Papadopoulos,R D Finn,O A Gansow,W H Miller Jr,M W Geerlings,R P Warrell Jr,S M Larson

1995-12-01

Abstract:M195, a mouse monoclonal antibody reactive with the early myeloid antigen CD33, has been shown to target leukemia cells in patients and to reduce large leukemic burdens when labeled with 131I. A complementarity-determining region-grafted, humanized version (HuM195) has demonstrated similar targeting of leukemia cells without immunogenicity. We have studied two applications of therapy with 131I-M195. First, to intensify therapy prior to bone marrow transplantation (BMT), we combined 131I-M195 with busulfan and cyclophosphamide. Fifteen patients received first BMT for relapsed or refractory acute myelogenous leukemia or accelerated or blastic chronic myelogenous leukemia; four received second BMT for relapsed chronic or accelerated chronic myelogenous leukemia. Doses of 131I-M195 ranged from 120 to 230 mCi/m2. Few toxicities could be attributed to 131I-M195 therapy, and all patients engrafted. Eighteen patients achieved complete remission. Among those patients receiving first BMT, three have remained in unmaintained remission for 18+ to 29+ months. Six patients relapsed, including one with isolated central nervous system disease 32 months after BMT. Ten patients died in complete remission of transplant-related complications. Second, we studied whether 131I-M195 could reduce minimal residual disease and prolong remission and survival durations safely in patients with relapsed acute promyelocytic leukemia after they attained remission with all-trans-retinoic acid. Seven patients were treated with either 50 or 70 mCi/m2 131I-M195. Toxicity was limited to myelosuppression. As a measure of minimal residual disease, we monitored PML/RAR-alpha mRNA by reverse transcription PCR. Six patients had positive reverse transcription PCR assays prior to receiving 131I-M195; two converted transiently to negative. Median disease-free survival and overall survival of the seven patients were 8 (range, 3-14.5) months and 28 (range, 5.5-43+) months, respectively. This regimen compares favorably with others for relapsed acute promyelocytic leukemia. In an effort to avoid nonspecific cytotoxicity associated with 131I in future trials for minimal residual disease, we have conjugated short-range, alpha particle-emitting radioisotopes to HuM195 using a bifunctional chelate, 2-(p-isothiocyanatobenzyl)-cyclohexyldiethyl-enetriaminep entaacetic acid, with high efficiency and specific activities. 212Bi-HuM195 has demonstrated dose- and specific activity-dependent killing of HL60 cells in vitro. Injection of 213Bi-HuM195 into healthy BALB/c mice produced no effects on weight or viability.
Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.

T M Behr,R M Sharkey,M E Juweid,R M Dunn,R C Vagg,Z Ying,C H Zhang,L C Swayne,Y Vardi,J A Siegel,D M Goldenberg

1997-01-01

Journal of Nuclear Medicine

Abstract:The aim of this study was to determine, in a Phase I/II clinical trial, the pharmacokinetics, dosimetry and toxicity, as well as antitumor activity, of the I-131-labeled murine anti-carcinoembryonic antigen (CEA) monoclonal antibody, NP-4 (IgG(1) subtype). Methods: A total of 57 patients with CEA-expressing tumors (29 colorectal, 9 lung, 7 pancreas, 6 breast and 4 medullary thyroid cancer patients), mostly in very advanced stages, were treated. The patients underwent a diagnostic study (1-3 mg of IgG and 8-30 mCi of I-131) to assess tumor targeting and to estimate dosimetry, followed by the therapeutic dose (4-23 mg and 44-268 mCi), based on the radiation dose to the red marrow. Imaging was performed from 4-240 hr postinjection (planar and SPECT). Blood and whole-body clearance were determined; radiation doses were calculated by the Medical Internal Radiation Dose scheme. Results: Red marrow doses ranged from 45 to 706 cGy, and whole-body doses ranged from 31 to 344 cGy. Differences in pharmacokinetics were found between different types of CEA-producing tumors: blood T-1/2 was significantly lower in colorectal cancer when compared to all other tumor types (21.4 +/- 11.1 hr versus 35.8 +/- 13.2 hr; p < 0.01), as was also whole-body t(1/2). Myelotoxicity was dose-limiting, and its severity was related to the types of prior therapy and extent of bone marrow involvement. In patients without prior radiation or chemotherapy, marrow doses as high as 600 cGy were tolerated without evidence of dose-limiting toxicity. No major toxicity to other organs was observed. Tumor doses were inversely related to the tumor mass and ranged between 2 and 218 cGy/mCi. Modest antitumor effects were seen in 12 of 35 assessable patients (1 partial remission, 4 minor/mixed responses and 7 with stabilization of previously rapidly progressing disease). Conclusion: These results suggest that prior chemotherapy or external beam radiation is an important risk factor for the development oi hematological toxicity in radioimmunotherapy and that higher radiation doses may be delivered to tumors of patients without prior therapy compromising the bone marrow reserve. The different and, in the individual cases, unpredictable clearance rates suggest the necessity of dosimetry-based treatment planning rather than mCi/m(2) dosing. Small tumors seem to be more suitable for radioimmunotherapy because of their favorable dosimetry, but to achieve better therapeutic results in patients with bulky disease, the application of higher, potentially myeloablative doses is indicated.
CD38-Targeted Theranostics of Lymphoma with 89Zr/177Lu-Labeled Daratumumab.

Lei Kang,Cuicui Li,Zachary T Rosenkrans,Nan Huo,Zhao Chen,Emily B Ehlerding,Yan Huo,Carolina A Ferreira,Todd E Barnhart,Jonathan W Engle,Rongfu Wang,Dawei Jiang,Xiaojie Xu,Weibo Cai

DOI: https://doi.org/10.1002/advs.202001879

2021-01-01

Abstract:Lymphoma is a heterogeneous disease with varying clinical manifestations and outcomes. Many subtypes of lymphoma, such as Burkitt's lymphoma and diffuse large B cell lymphoma, are highly aggressive with dismal prognosis even after conventional chemotherapy and radiotherapy. As such, exploring specific biomarkers for lymphoma is of high clinical significance. Herein, a potential marker, CD38, is investigated for differentiating lymphoma. A CD38-targeting monoclonal antibody (mAb, daratumumab) is then radiolabeled with Zr-89 and Lu-177 for theranostic applications. As the diagnostic component, the Zr-89-labeled mAb is highly specific in delineating CD38-positive lymphoma via positron emission tomography (PET) imaging, while the Lu-177-labeled mAb serves well as the therapeutic component to suppress tumor growth after a one-time administration. These results strongly suggest that CD38 is a lymphoma-specific marker and prove that 89Zr/177Lu-labeled daratumumab facilitates immunoPET imaging and radioimmunotherapy of lymphoma in preclinical models. Further clinical evaluation and translation of this CD38-targeted theranostics may be of significant help in lymphoma patient stratification and management.
212Pb α-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study

Isabelle Quelven,Jacques Monteil,Magali Sage,Amal Saidi,Jérémy Mounier,Audrey Bayout,Julie Garrier,Michel Cogne,Stéphanie Durand-Panteix

DOI: https://doi.org/10.2967/jnumed.119.239491

Abstract:Multiple myeloma (MM) is a plasma cell cancer and represents the second most frequent hematologic malignancy. Despite new treatments and protocols, including high-dose chemotherapy associated with autologous stem cell transplantation, the prognosis of MM patients is still poor. α-radioimmunotherapy (α-RIT) represents an attractive treatment strategy because of the high-linear-energy transfer and short pathlength of α-radiation in tissues, resulting in high tumor cell killing and low toxicity to surrounding tissues. In this study, we investigated the potential of α-RIT with 212Pb-daratumumab (anti-hCD38), in both in vitro and in vivo models, as well as an antimouse CD38 antibody using in vivo models. Methods: Inhibition of cell proliferation after incubation of the RPMI8226 cell line with an increasing activity (0.185-3.7 kBq/mL) of 212Pb-isotypic control or 212Pb-daratumumab was evaluated. Biodistribution was performed in vivo by SPECT/CT imaging and after death. Dose-range-finding and acute toxicity studies were conducted. Because daratumumab does not bind the murine CD38, biodistribution and dose-range finding were also determined using an antimurine CD38 antibody. To evaluate the in vivo efficacy of 212Pb-daratumumab, mice were engrafted subcutaneously with 5 × 106 RPMI8226 cells. Mice were treated 13 d after engraftment with an intravenous injection of 212Pb-daratumumab or control solution. Therapeutic efficacy was monitored by tumor volume measurements and overall survival. Results: Significant inhibition of proliferation of the human myeloma RPMI8226 cell line was observed after 3 d of incubation with 212Pb-daratumumab, compared with 212Pb-isotypic control or cold antibodies. Biodistribution studies showed a specific tumoral accumulation of daratumumab. No toxicity was observed with 212Pb-daratumumab up to 370 kBq because of lack of cross-reactivity. Nevertheless, acute toxicity experiments with 212Pb-anti-mCD38 established a toxic activity of 277.5 kBq. To remain within realistically safe treatment activities for efficacy studies, mice were treated with 185 kBq or 277.5 kBq of 212Pb-daratumumab. Marked tumor growth inhibition compared with controls was observed, with a median survival of 55 d for 277.5 kBq of 212Pb-daratumumab instead of 11 d for phosphate-buffered saline. Conclusion: These results showed 212Pb-daratumumab to have efficacy in xenografted mice, with significant tumor regression and increased survival. This study highlights the potency of α-RIT in MM treatment.
A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma

Elodie Duray,Margaux Lejeune,Frederic Baron,Yves Beguin,Nick Devoogdt,Ahmet Krasniqi,Yoline Lauwers,Yong Juan Zhao,Matthias D’Huyvetter,Mireille Dumoulin,Jo Caers

DOI: https://doi.org/10.1186/s13045-021-01171-6

2021-11-02

Abstract:Abstract Background Antibody-based therapies targeting CD38 are currently used as single agents as well as in combination regimens for multiple myeloma, a malignant plasma cell disorder. In this study, we aimed to develop anti-CD38 single-domain antibodies (sdAbs) that can be used to trace CD38 + tumour cells and subsequently used for targeted radionuclide therapy. SdAbs are derived from Camelidae heavy-chain antibodies and have emerged as promising theranostic agents due to their favourable pharmacological properties. Methods Four different anti-CD38 sdAbs were produced, and their binding affinities and potential competition with the monoclonal antibody daratumumab were tested using biolayer interferometry. Their binding kinetics and potential cell internalisation were further studied after radiolabelling with the diagnostic radioisotope Indium-111. The resulting radiotracers were evaluated in vivo for their tumour-targeting potential and biodistribution through single-photon emission computed tomography (SPECT/CT) imaging and serial dissections. Finally, therapeutic efficacy of a lead anti-CD38 sdAb, radiolabelled with the therapeutic radioisotope Lutetium-177, was evaluated in a CD38 + MM xenograft model. Results We retained anti-CD38 sdAb #2F8 as lead based on its excellent affinity and superior stability, the absence of competition with daratumumab and the lack of receptor-mediated internalisation. When intravenously administered to tumour-xenografted mice, radiolabelled sdAb #2F8 revealed specific and sustained tumour retention with low accumulation in other tissues, except kidneys, resulting in high tumour-to-normal tissue ratios. In a therapeutic setting, myeloma-bearing mice received three consecutive intravenous administrations of a high (18.5 MBq) or a low radioactive dose (9.3 MBq) of 177 Lu-DTPA-2F8 or an equal volume of vehicle solution. A dose-dependent tumour regression was observed, which translated into a prolonged median survival from 43 days for vehicle-treated mice, to 62 days ( p = 0.027) in mice receiving the low and 65 days in mice receiving the high ( p = 0.0007) radioactive dose regimen, respectively. Conclusions These results highlight the theranostic potential of radiolabelled anti-CD38 sdAbs for the monitoring and treatment of multiple myeloma.

oncology,hematology
Therapeutic Advantage Of (90)Yttrium-Versus (131)Iodine-Labeled Pam4 Antibody In Experimental Pancreatic Cancer

Tm Cardillo,Zl Ying,Dv Gold

2001-01-01

Abstract:Objectives: Radioimmunotherapy studies using I-131-PAM4 have demonstrated significant antitumor effects in mice bearing human pancreatic cancer xenografts. For several reasons Y-90 has been proposed as a more effective radionuclide for radioimmunotherapy of pancreatic cancer. The present study examined whether one radionuclide was more efficacious than the other in tumor-bearing mice.Methods: Athymic nude mice bearing CaPan1 xenograft tumors (similar to1.0 cm(3)) were given increasing doses of either Y-90-PAM4 or I-131-PAM4 up to their respective maximal tolerated doses [MTDs (260 and 700 mu Ci, respectively)].Results: Y-90-PAM4 provided significantly greater growth inhibition than the I-131-PAM4 (P < 0.035). Median survival time for the untreated mice was 6 weeks, whereas median survival times for the I-131-treated mice and Y-90-treated mice at their respective MTDs were 17.5 weeks and > 26 weeks (the end of the study period), respectively. Within the I-131-PAM4-treated group, two of eight mice were responders (> 50% decrease in tumor size) for a median of 14 weeks. At the end of the study (26 weeks), I mouse was alive with no sign of tumor. All of the Y-90-PAM4-treated mice were responders with a median duration of response of 20 weeks. Six of the seven mice were alive at week 26, with four mice having no evidence of disease.Conclusions: These data demonstrate the advantage of Y-90 over I-131 as the radionuclide for PAM4-targeted radioimmunotherapy of xenografted pancreatic cancer. Furthermore, the duration and extent of the antitumor response suggests that multiple treatment cycles of Y-90-PAM4 may provide an effective therapeutic for the control of pancreatic cancer.
Cysteine-specific 89Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas

Jin Hee Lee,Kyung-Ho Jung,Mina Kim,Kyung-Han Lee

DOI: https://doi.org/10.3389/fimmu.2022.1017132

IF: 7.3

2022-12-15

Frontiers in Immunology

Abstract:Introduction Positron emission tomography (PET) using radiolabeled Abs as imaging tracer is called immuno-PET. Immuno-PET can verify therapeutic Ab delivery and can noninvasively quantify global levels of target expression in tumors of living subjects. The interleukin-2 receptor α chain (IL-2Rα; CD25) is a promising target for immune therapy and radioimmunotherapy of lymphomas. Immuno-PET could facilitate this approach by visualizing CD25 expression in vivo . Methods We prepared 89 Zr-anti-CD25 IgG specifically labeled to sulfhydryl moieties by maleimide-deferoxamine conjugation. Results and Discussion CD25(+) SUDHL1 human T-cell lymphoma cells showed high anti-human 89 Zr-CD25 IgG binding that reached 32-fold of that of CD25(-) human lymphoma cells and was completely blocked by excess unlabeled Ab. In SUDHL1 tumor-bearing nude mice, pharmacokinetic studies demonstrated exponential reductions of whole blood and plasma activity following intravenous 89 Zr-anti-CD25 IgG injection, with half-lives of 26.0 and 23.3 h, respectively. SUDHL1 tumor uptake of 89 Zr-CD25 IgG was lower per weight in larger tumors, but blood activity did not correlate with tumor size or blood level of human CD25, indicating minimal influence by circulating soluble CD25 protein secreted from the lymphoma cells. 89 Zr-CD25 IgG PET allowed high-contrast SUDHL1 lymphoma visualization at five days. Biodistribution studies confirmed high tumor 89 Zr-CD25 IgG uptake (8.7 ± 0.9%ID/g) that was greater than blood (5.2 ± 1.6%ID/g) and organ uptakes (0.7 to 3.5%ID/g). Tumor CD25-specific targeting was confirmed by suppression of tumor uptake to 4.3 ± 0.2%ID by excess unlabeled CD25 IgG, as well as by low tumor uptake of 89 Zr-labeled IgG2a isotype control Ab (3.6 ± 0.9%ID). Unlike CD25(+) lymphocytes from mouse thymus that showed specific uptake of anti-mouse 89 Zr-CD25 IgG, EL4 mouse lymphoma cells had low CD25 expression and showed low uptake. In immunocompetent mice bearing EL4 tumors, anti-mouse 89 Zr-CD25 IgG displayed low uptakes in normal organs as well as in the tumor. Furthermore, the biodistribution was not influenced by Ab blocking, indicating that specific uptake in nontumor tissues was minimal. 89 Zr-CD25 IgG immuno-PET may thus be useful for imaging of T-cell lymphomas and noninvasive assessment of CD25 expression on target cells in vivo .

immunology
High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab

Tobias Weber,Benedikt Bötticher,Walter Mier,Max Sauter,Susanne Krämer,Karin Leotta,Armin Keller,Anne Schlegelmilch,Ludger Grosse-Hovest,Dirk Jäger,Uwe Haberkorn,Michaela A. E. Arndt,Jürgen Krauss

DOI: https://doi.org/10.1007/s00259-015-3175-6

2015-09-04

Abstract:PurposeDual-targeted therapy has been shown to be a promising treatment option in recurrent and/or refractory B-cell non-Hodgkin’s lymphoma (B-NHL). We generated radioimmunoconjugates (RICs) comprising either a novel humanized anti-CD22 monoclonal antibody, huRFB4, or rituximab, and the low-energy β-emitter 177Lu. Both RICs were evaluated as single agents in a human Burkitt’s lymphoma xenograft mouse model. To increase the therapeutic efficacy of the anti-CD22 RIC, combination therapy with unlabelled anti-CD20 rituximab was explored.MethodsThe binding activity of CHX-A″-DTPA-conjugated antibodies to target cells was analysed by flow cytometry. To assess tumour targeting of 177Lu-labelled antibodies, in vivo biodistribution experiments were performed. For radioimmunotherapy (RIT) studies, non-obese diabetic recombination activating gene-1 (NOD-Rag1null) interleukin-2 receptor common gamma chain (IL2rγ null) null mice (NRG mice) were xenografted subcutaneously with Raji Burkitt’s lymphoma cells. 177Lu-conjugated antibodies were administered at a single dose of 9.5 MBq per mouse. For dual-targeted therapy, rituximab was injected at weekly intervals (0.5 – 1.0 mg). Tumour accumulation of RICs was monitored by planar scintigraphy.ResultsConjugation of CHX-A”-DTPA resulted in highly stable RICs with excellent antigen-binding properties. Biodistribution experiments revealed higher tumour uptake of the 177Lu-labelled anti-CD22 IgG than of 177Lu-labelled rituximab. Treatment with 177Lu-conjugated huRFB4 resulted in increased tumour growth inhibition and significantly longer survival than treatment with 177Lu-conjugated rituximab. The therapeutic efficacy of the anti-CD22 RIC could be markedly enhanced by combination with unlabelled rituximab.ConclusionThese findings suggest that dual targeting with 177Lu-based CD22-specific RIT in combination with rituximab is a promising new treatment option for refractory B-NHL.

Psychological Effects During Reduced Training in Distance Runners*

P925: PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA

Radioligand Therapy in Lymphoma: Past, Present, and Future

Safety and dosimetry evaluation of radioimmunotherapy using 177Lu-labeled antibodies in lymphoma

Integrated DC-DC converter with an auxiliary output stage for transient suppression

Cure of Disseminated Human Lymphoma with [177Lu]Lu-Ofatumumab in a Preclinical Model

Targeted Alpha Therapy with [225Ac]Ac-Macropa-Isatuximab for CD38-positive Hematological Malignancies

CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma

CD46-targeted theranostics for Positron Emission Tomography and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma

A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma

Effect of 67Cu-2It-bat-lym-1 Therapy on BCL-2 Gene and Protein Expression in a Lymphoma Mouse Model.

Theranostics of Lymphoma with 89Zr- and 177Lu-Labeled Daratumumab

Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation

Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias

Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.

CD38-Targeted Theranostics of Lymphoma with 89Zr/177Lu-Labeled Daratumumab.

212Pb α-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study

A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma

Therapeutic Advantage Of (90)Yttrium-Versus (131)Iodine-Labeled Pam4 Antibody In Experimental Pancreatic Cancer

Cysteine-specific 89Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas

High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab